$Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer$
Código QR

Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer

Patients with refractory metastatic triple-negative breast cancer (mTNBC) and symptomatic brain metastases have poor prognosis and are challenging to treat. The addition of an programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitor (pembrolizumab or atezolizumab) to first lin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hongyuan Zhao, Weijie Ma, Ruben C. Fragoso, Griffith R. Harsh IV, Arya Ashok, Tianhong Li
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Multidisciplinary Immune checkpoint inhibitor Pdj amplification Triple-negative breast cancer Brain metastasis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b0207e3a22944f94890d61ef2e6ba3ed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer

Ejemplares similares